Loop Diuretics and Mortality in Heart Failure: A Propensity Score–Matched Study
Open Access
- 1 January 2026
- journal article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Abstract
Background: While loop diuretics remain a cornerstone of heart failure (HF) management, evidence directly comparing the clinical outcomes of torasemide and furosemide is still not clear. Objectives: We aimed to assess the comparison of mortality between furosemide and torasemide in patients with HF. Methods: This single‐center, retrospective, and observational cohort study included 627 patients with HF who were regularly prescribed furosemide or torasemide and were admitted to the emergency department or cardiology outpatient clinic between January 1, 2022, and June 30, 2023. Patients were divided into the two groups as follows: the furosemide group and the torasemide group. The primary outcome was defined as 1‐year all‐cause mortality. The primary outcome was assessed by Kaplan−Meier analyses in the whole study population and the 1:1 propensity score−matched cohort. Results: Of 627 eligible patients with HF, 497 were treated with furosemide, while 130 received torasemide. After propensity score matching analysis, 82 patients with HF in the furosemide group were compared with 82 patients with HF in the torasemide group. In the furosemide group, 1‐year all‐cause mortality was observed in 15 (18.3%) patients with HF, compared to 13 (15.9%) patients with HF in the torasemide group ( p : 0.678). Kaplan−Meier analysis showed that cumulative survival rates were comparable between the HF patients treated with furosemide and those treated with torasemide (log‐rank p : 0.661). Conclusions: In patients with HF, treatment with torasemide was associated with similar 1‐year all‐cause mortality compared to furosemide, underscoring the absence of a detectable prognostic difference between the two loop diuretic strategies.Keywords
This publication has 24 references indexed in Scilit:
- On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HFEuropean Journal of Heart Failure, 2024
- Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2023
- Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart FailureJAMA, 2023
- Proteomic differences among patients with heart failure taking furosemide or torsemideClinical Cardiology, 2022
- Dose of Furosemide Before Admission Predicts Diuretic Efficiency and Long-Term Prognosis in Acute Heart FailureESC Heart Failure, 2021
- Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trialsHeart Failure Reviews, 2020
- Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of CardiologyCardiovascular Drugs and Therapy, 2019
- Investigating a Biomarker-Driven Approach to Target Collagen Turnover in Diabetic Heart Failure with Preserved Ejection Fraction Patients. Effect of Torasemide Versus Furosemide on Serum C-Terminal Propeptide of Procollagen Type I (DROP-PIP trial)European Journal of Heart Failure, 2017
- Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)The American Journal of Cardiology, 2016
- A reappraisal of loop diuretic choice in heart failure patientsAmerican Heart Journal, 2015